Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06611163 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
A Phase 3 study of Moderate to Severe Genital Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.
- Active
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT06611163: Active Phase 3 study of Moderate to Severe Genital Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.
NCT06611163 is a Phase 3 study of Moderate to Severe Genital Psoriasis that is active but no longer recruiting, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 206 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06611163, a Phase 3 study of Moderate to Severe Genital Psoriasis, is active but no longer recruiting, sponsored by Sun Pharmaceutical Industries Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Primary Outcome
The modified sPGA-G is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4) and incorporates an assessment of the severity of the three primary signs of the disease: erythema, elevation, and scaling. Higher scores indicate greater disease severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tildrakizumab 100 mg
Study Locations (20)
California
- Smary Cures Clinical Research - Anaheim
- California Dermatology & Clinical Research Institute - Encinitas
- T. Joseph Raoof MD, Inc./Encino Research Center - Encino
- Center for Dermatology Clinical Research, Inc - Fremont
- Dermatology Research Associates - Los Angeles
- LA Universal Research Center Inc, Suite 1 - Los Angeles
- Amicis Research Center - Northridge
- Therapeutics Clinical Research - San Diego
- Dermatology Institute and Skin Care Center, Inc. DBA Clinical Science Institute - Santa Monica
Florida
- Coral Gables Dermatology & Aesthetics - Coral Gables
- Florida Academic Centers Research and Education, LLC - Coral Gables
- Homestead Associates in Research Inc - Homestead
- Genomics Medical Research - Miami
- Med-Care Research - Miami
Georgia
- Dermatology Affiliates Research Institute, LLC - Atlanta
- Mcintosh Clinic, PC - Thomasville
Michigan
- Oakland Hills Dermatology PC - Auburn Hills
- The Derm Institute of West Michigan - Caledonia
Colorado
- Paradigm Clinical Research - Wheat Ridge
Indiana
- The Indiana Clinical Trials Center - Plainfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2027-02 |
| Phase | Phase 3 |
What the registry record for NCT06611163 still lists
NCT06611163 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Moderate to Severe Genital Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06611163 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06611163 about?
NCT06611163 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.". Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
What is the current status of trial NCT06611163?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2025-03-21. Estimated completion is 2027-02.
What conditions does trial NCT06611163 study?
This clinical trial studies the following conditions: Moderate to Severe Genital Psoriasis.
What interventions are being tested in trial NCT06611163?
The interventions under investigation include: Placebo (DRUG), Tildrakizumab 100 mg (DRUG).
Who is sponsoring clinical trial NCT06611163?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06611163 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06611163's enrollment target sits among peer trials
206 1348th of 2000 higher than 651 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI